Autolus announces changes to its Board and Management Team
August 04 2020 - 7:00AM
Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage
biopharmaceutical company developing next-generation programmed T
cell therapies, today announced the appointment of Dr. Jay T
Backstrom to its Board of Directors, effective August 1, 2020. Dr.
Backstrom currently serves as EVP, Head of Research &
Development at Acceleron Pharma Inc (Acceleron) and prior to that
served as Chief Medical Officer and Head of Regulatory Affairs at
Celgene Corporation. Additionally, the Company announced that Dr.
Nushmia Khokhar has been promoted to Senior Vice President,
Clinical Development, and will take over the medical leadership
role at Autolus. Dr. Khokhar is a board-certified oncologist
with extensive early and late stage clinical development
experience, having led several successful registration trials
within the industry including the global daratumumab program at
Janssen Oncology. Dr. Vijay Peddareddigari, Senior Vice President,
Chief Medical Officer, is leaving the Company to return to the US.
“We are delighted with Dr. Jay Backstrom’s
appointment to the Board of Directors. Jay brings a wealth of
oncology development, regulatory and portfolio strategy experience
to the board. Under his leadership Celgene has developed a broad
range of therapeutics, including small molecules, biologicals and
CAR T programs, in one of the industry’s most significant
hemato-oncology pipelines,” said Dr. Christian Itin, chairman and
chief executive officer of Autolus. “It is my pleasure to
congratulate Dr. Nushmia Khokhar on her appointment as Senior Vice
President, Clinical Development and on joining the executive team.
Nushmia has been instrumental in overseeing the development of our
clinical programs and we look forward to her continued strong
leadership. I would also like to thank Vijay for his significant
contributions to Autolus and wish him well in his future endeavors.
Over the past four years he has played a key leadership role in
establishing and executing the clinical development strategy to
advance our programmed T cell therapies.”
Dr. Backstrom currently serves as EVP, Head of
Research & Development at Acceleron, a role that he has held
since December 2019. Prior to that, he spent 10 years at Celgene
where he latterly served as Chief Medical Officer and Head of
Regulatory Affairs with a focus in hematology/oncology. Prior to
Celgene, he served as Vice President, Global Medical Affairs and
Safety at Pharmion. Dr. Backstrom began his career in industry in
1990 at Marion Merrell Dow and continued as part of its successor
companies including Hoechst Marion Roussel, where he held positions
in Clinical Research and Global Drug Surveillance and
Pharmacoepidemiology. He also spent nearly three years at Quintiles
in Medical and Scientific Services, including Therapeutic Head,
Cardiovascular, Respiratory and Critical Care, where he oversaw
extensive clinical work across a variety of cardiovascular and
pulmonary diseases.
Prior to his move to industry, Dr. Backstrom
served as staff physician and Medical Director of the Samuel U.
Rodgers Community Health Center in Kansas City, Missouri. Dr.
Backstrom holds an M.D. from Temple University School of Medicine
and received post-graduate training in Internal Medicine at Temple
University Hospital. He also earned a Master’s in Public Health
from Saint Louis University School of Public Health.
About Autolus Therapeutics
plcAutolus is a clinical-stage biopharmaceutical company
developing next-generation, programmed T cell therapies for the
treatment of cancer. Using a broad suite of proprietary and modular
T cell programming technologies, the company is engineering
precisely targeted, controlled and highly active T cell therapies
that are designed to better recognize cancer cells, break down
their defense mechanisms and eliminate these cells. Autolus has a
pipeline of product candidates in development for the treatment of
hematological malignancies and solid tumors. For more information
please visit www.autolus.com.
Contact:
Lucinda Crabtree, PhDVice President, Investor
Relations and Corporate Communications+44 (0) 7587 372
619 l.crabtree@autolus.com
Julia Wilson+44 (0) 7818
430877j.wilson@autolus.com
Susan A. NoonanS.A. Noonan
Communications+1-212-966-3650susan@sanoonan.com
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Sep 2023 to Sep 2024